| Literature DB >> 23143890 |
Wei Zhou1, Yi Liu, De-Wu Zhong.
Abstract
Associations between adiponectin (ADIPOQ) genetic polymorphisms (rs2241766 G/T and rs266729 G/C) and cancer risk have been extensively studied in the past decade, while conflicting results were reported. Therefore, this study would explore the associations by using a meta-analysis. The databases of Medline, Embase, and Wangfang were retrieved, and the latest updated time was 1 August 2012. Effect sizes of odds ratio and 95 % confidence interval (OR and 95 % CI) were calculated by using a fixed- or random-effect model. A total of 12 studies with 10,368 participants were identified for association between ADIPOQ rs2241766 G/T and risk of cancer, and ten studies with 12,665 participants were for association between ADIPOQ rs266729 G/C and risk of cancer. Overall combined analyses indicated that neither ADIPOQ rs2241766 G/T nor rs266729 G/C was associated with risk of cancer incidence (OR (95 % CI), 0.89 (0.61-1.30) for GG vs. TT and 0.94 (0.83-1.06) for G carriers vs. T carriers for rs2241766 G/T; 0.99 (0.85-1.16) for GG vs. CC and 0.96 (0.87-1.06) for G carriers vs. C carriers for rs266729 G/C). When stratified analyses were conducted according to the participants' ethnicity, sources of controls, types of cancer, and sample size, we found that G allele of ADIPOQ rs2241766 G/T was significantly associated with decreased risk of cancer based on population-based case-control studies (OR (95 % CI), 0.65 (0.50-0.85) for GG vs. TT and 0.88 (0.79-0.98) for G carriers vs. T carriers). In contrast, there was no association between rs266729 G/C polymorphism and risk of cancer when subgroup analyses were conducted. In summary, this meta-analysis indicated that ADIPOQ rs2241766 G/T rather than rs266729 G/C polymorphism was closely associated with risk of cancer development.Entities:
Mesh：
Substances：
Year: 2012 PMID： 23143890 DOI： 10.1007/s13277-012-0574-1
Source DB: PubMed Journal: Tumour Biol ISSN： 1010-4283